Drugs & Aging

, Volume 30, Issue 11, pp 871–876

Management of Inflammatory Bowel Disease in the Elderly: Do Biologicals Offer A Better Alternative?

Current Opinion

Abstract

The management of inflammatory bowel disease (IBD) in elderly patients provides added complexity for healthcare providers who need to take into account the high likelihood of co-morbid disease, the need for polypharmacy and, in many instances, greater patient fragility. While biologics are often considered first-line corticosteroid-sparing strategies for moderate to severe disease, the additional variables unique to an elderly patient warrant consideration when discussing IBD therapeutics. As chronic corticosteroid use, although relatively common among older IBD patients, is suboptimal, the efficacy and safety of biologics compared with immunomodulators among older IBD patients needs additional investigation.

References

  1. 1.
    Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907–13.PubMedCrossRefGoogle Scholar
  2. 2.
    2010 Census Data on Aging. Available at http://www.aoa.gov/aoaroot/aging_statistics/Census_Population/census2010/Index.aspx. Last modified December 5, 2011.
  3. 3.
    Khalili H, Huang ES, Ananthakrishnan AN, et al. Geographical variation and incidence of inflammatory bowel disease among US women. Gut. 2012;61:1686–92.PubMedCrossRefGoogle Scholar
  4. 4.
    Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gut. 2000;46:336–43.PubMedCrossRefGoogle Scholar
  5. 5.
    Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Crohn’s disease in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gastroenterology. 1998;114:1161–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2013. doi:10.1136/gutjnl-2012-303864.
  7. 7.
    Quezada SM, Steinberger EK, Cross RK. Association of age at diagnosis and Crohn’s disease phenotype. Age Ageing. 2013;42(1):102–6.Google Scholar
  8. 8.
    Ha CY, Newberry RD, Stone CD, et al. Patients with late-adult-onset ulcerative colitis have better outcomes than those with early onset disease. Clin Gastroenterol Hepatol. 2010;8(8):682–7.Google Scholar
  9. 9.
    Juneja M, Baidoo L, Schwartz MB, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57:2408–15.PubMedCrossRefGoogle Scholar
  10. 10.
    Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis. 2000;31:578–85.PubMedCrossRefGoogle Scholar
  11. 11.
    Pawelec G. Immunosenescence: impact in the young as well as the old? Mech Ageing Dev. 1999;108:1–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Cucchiara S, Iebba V, Conte MP, et al. The microbiota in inflammatory bowel disease in different age groups. Dig Dis. 2009;27:252–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Tourner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–36.CrossRefGoogle Scholar
  14. 14.
    Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107(9):1409–22.Google Scholar
  15. 15.
    Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621–30.PubMedCrossRefGoogle Scholar
  16. 16.
    Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis. 2009;15:182–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:2272–80.PubMedCrossRefGoogle Scholar
  18. 18.
    Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis. 2013;7(2):107–12.Google Scholar
  19. 19.
    Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205–10.PubMedCrossRefGoogle Scholar
  20. 20.
    Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology. 2005;128:862–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004;126:402–13.PubMedCrossRefGoogle Scholar
  22. 22.
    Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95.PubMedCrossRefGoogle Scholar
  23. 23.
    Rubin DT, Uluscu O, Sederman R. Response to biologic therapy in Crohn’s disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis. 2012;18:2225–31.PubMedCrossRefGoogle Scholar
  24. 24.
    Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn’s disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105:1574–82.PubMedCrossRefGoogle Scholar
  25. 25.
    Benchimol EI, Cook SF, Erichsen R, et al. International variation in medication prescription rates among elderly patients with inflammatory bowel disease. J Crohns Colitis. 2012. doi:10.1016/j.crohns.2012.09.001.
  26. 26.
    Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Desai A, Zator ZA, de Silva P, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;19:309–15.Google Scholar
  28. 28.
    Moleski S, Lindenmeyer C, Kozuch P. The use of infliximab in older inflammatory bowel disease patients. Gastroenterology. 2012;142:S361.Google Scholar
  29. 29.
    Bhushan A, Pardi D, Loftus E, et al. Association of age with adverse events from biologic therapy in patients with inflammatory bowel disease. Gastroenterology. 2010;138:A413.Google Scholar
  30. 30.
    Marehbian J, Arrighi HM, Hass S, et al. Adverse events associated with common therapy regimens for moderate-to-severe Crohn’s disease. Am J Gastroenterol. 2009;104:2524–33.PubMedCrossRefGoogle Scholar
  31. 31.
    Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. J Am Med Assoc. 2011;306:2331–9.CrossRefGoogle Scholar
  32. 32.
    Tran S, Hooker RS, Cipher DJ, et al. Patterns of biologic agent use in older males with inflammatory diseases: an institution-focused, observational post-marketing study. Drugs Aging. 2009;26:607–15.PubMedCrossRefGoogle Scholar
  33. 33.
    Oei HB, Hooker RS, Cipher DJ, et al. High rates of stopping or switching biological medications in veterans with rheumatoid arthritis. Clin Exp Rheumatol. 2009;27:926–34.PubMedGoogle Scholar
  34. 34.
    Ha CY, Katz S. Clinical outcomes and management of inflammatory bowel disease in the older patient. Curr Gastroenterol Rep. 2013;15:310.PubMedCrossRefGoogle Scholar
  35. 35.
    Baddley JW, Winthrop KL, Patkar NM, et al. Geographic distribution of endemic fungal infections among older persons, United States. Emerg Infect Dis. 2011;17:1664–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Widdifield J, Bernatsky S, Michael Paterson J, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res. 2013;65(3):353-61.Google Scholar
  37. 37.
    Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143(390–399):e1.PubMedGoogle Scholar
  38. 38.
    Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56:2886–95.PubMedCrossRefGoogle Scholar
  39. 39.
    Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141:1621–28. e1–5.Google Scholar
  40. 40.
    Beaugerie L, Carrat F, Bouvier AM, et al. Excess risk of lymphoproliferative disorders (LPD) in inflammatory bowel disease (IBD): interim results of the CESAME cohort. Gastroenterology. 2008;134:A116–7.CrossRefGoogle Scholar
  41. 41.
    Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268–74.PubMedCrossRefGoogle Scholar
  42. 42.
    Dixon WG, Watson KD, Lunt M, et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res. 2010;62:755–63.CrossRefGoogle Scholar
  43. 43.
    Raaschou P, Simard JF, Neovius M, et al. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum. 2011;63:1812–22.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Division of Digestive DiseasesDavid Geffen School of Medicine at UCLALos AngelesUSA
  2. 2.Division of GastroenterologyNYU Langone Medical CenterNew YorkUSA

Personalised recommendations